AbClon Inc. (KOSDAQ:174900)
23,700
-900 (-3.66%)
Sep 1, 2026, 3:30 PM KST
AbClon Revenue
AbClon had revenue of 1.68B KRW in the quarter ending June 30, 2026, with 51.44% growth. This brings the company's revenue in the last twelve months to 5.31B, up 75.02% year-over-year. In the year 2025, AbClon had annual revenue of 4.71B with 101.47% growth.
Revenue (ttm)
5.31B
Revenue Growth
+75.02%
P/S Ratio
92.47
Revenue / Employee
n/a
Employees
n/a
Market Cap
490.82B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.71B | 2.37B | 101.47% |
| Dec 31, 2024 | 2.34B | -537.21M | -18.67% |
| Dec 31, 2023 | 2.88B | -527.18M | -15.49% |
| Dec 31, 2022 | 3.40B | 386.15M | 12.79% |
| Dec 31, 2021 | 3.02B | 246.87M | 8.91% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GC Corp. | 2.49T |
| Chabiotech | 1.31T |
| Medy-Tox | 251.08B |
| Onconic Therapeutics | 82.17B |
| MEDIPOST | 74.84B |
| Komipharm International | 53.02B |
| Pharmicell | 23.94B |
| SillaJen | 10.92B |